REFERENCES
- Diasio RB. An evolving role for oral fluoropyrimidine drugs. J Clin Oncol 2002; 20: 894–6.
- Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 998–1002.
- Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–93.
- Blum JL, Dieras V, Lo Russo PM, et al. Phase II study of capecitabine in taxane-pre-treated metastatic breast carcinoma patients. Cancer 2001; 92: 1759–68.
- Reichardt P, von Mickwitz G, Luck HJ, et al. Capecetabine: the new standard in metastatic breast cancer failing anthracycline-and taxane-containing chemotherapy? Mature results of a large multicentre phase II trial. Eur J Cancer 2001; 37\(Suppl. 6): (Abstr 699).
- Fumoleau P, Largillier R, Trillet-Lenoir V, et al. Phase II study of capecitabine (Xeloda®) in patients with advanced breast cancer (ABC) previously treated with anthracyclines and tax-anes. Breast Cancer Res Treat 2001; 69: 285 (Abstr 435).
- Cervantes G, Torrecillas L, Erazo A, et al. Capecitabine (XELODA) as treatment after failure to taxanes for metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19: 121a (Abstr 469).
- Liu G, Franssen E, Fitch MI. Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–5.
- Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349–58.